Photo taken from Enes Erul/X
May 9, 2024, 00:21
Enes Erul: Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors
Enes Erul, Oncology Fellow at Ankara Üniversitesi, shared on X:
“Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors, with a 29.4% objective response rate in heavily treated patients. Safety profile manageable, supporting further investigation across tumor types.”
Source: Enes Erul/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023